Engineered Bacteriocin Tail Fiber Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibacterial agents are ineffective against antibiotic-resistant bacterial pathogens, particularly Pseudomonas aeruginosa, which poses a significant threat due to rising resistance and limited diagnostic and therapeutic options.
Innovation Solution
Engineered high molecular weight bacteriocins, such as modified R-type pyocins, with altered tail fibers and receptor binding domains, are developed to target specific bacterial strains, including those resistant to conventional antibiotics, by modifying the amino acid sequence or incorporating heterologous sequences from bacteriophage tail proteins to broaden their bactericidal spectrum.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used, then bacterial infections can be treated, but antibiotic-resistant bacteria emerge and render the antibiotics ineffective
Solution Approach 1:
The patent modifies the amino acid sequence of bacteriocin tail fibers to alter binding specificity and affinity parameters, enabling the bacteriocin to recognize and bind to different bacterial surface receptors that are not targeted by conventional antibiotics, thereby overcoming bacterial resistance
Solution Approach 2:
The patent creates chimeric tail fiber proteins by combining domains from different bacteriocins or bacteriophages, resulting in hybrid structures with novel binding specificities that can target antibiotic-resistant bacterial strains
2Adaptability or versatility
If the tail fiber amino acid sequence is modified to broaden bactericidal spectrum, then binding specificity and affinity are enhanced, but the structural complexity of the bacteriocin increases
Solution Approach 1:
The tail fiber protein is divided into functional domains (N-terminal baseplate-binding domain and C-terminal receptor-binding domain), allowing independent modification of the C-terminal domain to alter specificity without affecting the structural integrity or assembly of the N-terminal domain
Solution Approach 2:
The patent applies targeted amino acid substitutions, insertions, or deletions specifically in the C-terminal region of the tail fiber that contacts the bacterial receptor, leaving the rest of the protein structure unchanged to maintain proper folding and assembly
3Adaptability or versatility
If heterologous sequences from bacteriophage tail proteins are incorporated, then the bactericidal spectrum is broadened, but the difficulty of production increases
Solution Approach 1:
The patent uses modular genetic constructs where the heterologous receptor-binding domain is inserted into a standardized bacteriocin backbone with known expression characteristics, facilitating production in GRAS-status bacteria while maintaining the novel binding properties of the heterologous domain
Data Source
AI summary
Modified forms of naturally occurring bacteriocins, such as the R-type pyocins of Pseudomonas aeruginosa, are disclosed as are methods for producing them in GRAS organisms. The bacteriocins are modified at the ends of their tail fibers in a region responsible for binding specificity and affinity to their cognate binding partners, or receptors, such as those on the surface of bacteria. Methods for the use of the modified bacteriocins, such as to bind receptors, including virulence or fitness factors, on the surfaces of bacteria, are also described.